{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'approximately 3 months and 4.5 months, respectively. The increase of median', 'progression-free survival in rovalpituzumab tesirine arm corresponds to a hazard ratio of', '0.667. With all these assumptions, a total of approximately 420 PFS events assessed by', 'the CRAC for the subjects with DLL3high are needed to achieve a 91% power based on a', 'log-rank test at a one-sided significance level of 0.0025. It is projected that an observed', 'hazard ratio of 0.760 or less, corresponding to approximately 1 month or greater', 'improvement in median PFS, would result in a statistically significant improvement in the', 'PFS.', '8.5', 'Futility Analysis', 'A futility analysis will be conducted when approximately 160 deaths in subjects with', 'DLL3high ED SCLC (approximately 50% of the planned deaths) are observed. The trial', 'may be stopped for futility if the estimated Overall Survival Cox HR of Rova-T to', 'Placebo in the DLL3high set at futility analysis exceeds 0.9. The one-sided alpha of 10-6', 'will be spent for the early look at the efficacy data for futility analysis.', 'Unblinded interim data will be analyzed and reviewed by the IDMC. The trial may be', 'considered for early stopping for futility and the Sponsor will be unblinded to the', 'aggregated data by randomized treatment arms if the IDMC makes such a', 'recommendation after consideration of the OS results and other supportive evidence', 'including other relevant efficacy and safety data.', 'Details for the futility analysis will be provided in the IDMC charter.', '8.6', 'Accrual/Study Duration Considerations', 'On average, it is expected that accrual rates are 1, 7, 27, 36, and 42 with DLL3 high subjects', 'per month at study initiation, 3, 6, 9, and 12 month and thereafter, respectively. The total', 'study duration and accrual duration are projected to be 31 months and 19 months with a', '5% rate of loss to follow-up, respectively. A total of 740 subjects regardless of DLL3', 'expression level in tumor are expected to enroll during the accrual period. It is projected', 'that 480 subjects with DLL3 high ED SCLC will have enrolled for the primary analysis by', '106']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'the time approximately 420 PFS events per CRAC and at least 319 OS events should be', 'observed in DLL3 high subjects after approximately 8 - 10 months of follow-up.', '8.7', 'Randomization Methods', 'The randomization numbers of the study will assign subjects in a 1:1 ratio to either', 'receive 0.3 mg/kg rovalpituzumab tesirine or placebo, on Day 1 of each 6-week cycle,', 'omitting every third cycle. Randomization will be stratified by RECIST v1.1 response', 'after completion of first-line platinum-based therapy at screening assessment (SD VS.', 'PR/CR), DLL3 expression (Unknown VS. 0% to < 25% VS. 25% to < 75% VS. 75% or', 'above), history of CNS metastases (Yes VS. No), and for subjects with no history of CNS', 'metastases, PCI VS. no PCI.', '9.0', 'Ethics', '9.1', 'Independent Ethics Committee (IEC) or Institutional Review', 'Board (IRB)', 'Good Clinical Practice (GCP) requires that the clinical protocol, any protocol', \"amendments, the Investigator's Brochure, 14 the informed consent and all other forms of\", 'subject information related to the study (e.g., advertisements used to recruit subjects) and', 'any other necessary documents be reviewed by an IEC/IRB. The IEC/IRB will review the', 'ethical, scientific and medical appropriateness of the study before it is conducted.', 'IEC/IRB approval of the protocol, informed consent and subject information and/or', 'advertising, as relevant, will be obtained prior to the authorization of drug shipment to', 'a', 'study site.', 'Any amendments to the protocol will require IEC/IRB (Competent Authority, if', 'applicable) approval prior to implementation of any changes made to the study design.', 'The investigator will be required to submit, maintain and archive study essential', 'documents according to ICH GCP and all other applicable regulatory requirements.', 'Any serious adverse events that meet the reporting criteria, as dictated by local', 'regulations, will be reported to both responsible Ethics Committees and Regulatory', '107']\n\n###\n\n", "completion": "END"}